Abstract:Cell biology research has provided evidence that cell cycle checkpoints and DNA damage response pathways are coupled to circadian clocks. Accordingly, radiation therapy (RT) may result in variable tumor cell insult or normal tissue repair depending on the time of day delivered. Here, we reviewed the outcomes of patients treated for HNSCC with RT paying attention to the time of day patients receive RT. We reviewed patients definitively treated for HNSCC between 2006 and 2012 who met the following criteria: daily radiation treatment times/complete smoking history/staging/ECOG PS/RTOG toxicity scoring available, at least 2 yrs follow-up for alive patients. A total of 240 patients were included in the analysis. Endpoints included LRC, OS, CSS, and highest RTOG acute toxicity. Cox model was used to test the effect of the time of day that a patient was treated adjusted for age, sex, race, T stage, N stage, use of chemotherapy, smoking status, tumor site, RT modality, days elapsed during treatment and ECOG performance status. We calculated the median treatment time of day for each patient, and then we created a binary variable using noon as a cut point. We additionally calculated the standard variation in daily treatment time for each patient and considered correlation between median time of day or variation in daily treatment time and greatest RTOG toxicity score using spearman correlation. Data was analyzed using a statistical software package. Patient characteristics were as follows: median age=64 years; ECOG PS: 0-50%, 1-41%, 2-9%. Smoking status: 38% current smokers, 15% never smokers, 47% former smokers, median number of pack years =34. Site of disease: 48% OP, 12% OC, 29% larynx, 2% NP, 6%HP, 3% nasal cavity/paranasal sinus. RT modality: 57% IMRT, 43% 3DC. All patients completed 100% of prescribed dose which was 63-70Gy. At median follow-up of 24 months, overall LRC was 63%, CSS was 60%, and OS was 49%. Time of daily treatment significantly correlated with CSS (p=0. 0.0262, HR 1.837, 95% CI 1.075, 3.141) with AM patients having improved CSS. Additionally, there was a trend towards improved LRC (p= 0.0641, HR 1.569, 95% CI 0.974, .528) and OS (P=.1144, HR 1.531, 95% CI 0.902, 2.597) in the AM patients. Highest RTOG toxicity score was not significantly different between AM and PM patients. No correlation was seen between variation in daily treatment time and LRC, CSS, OS. Using Spearmen correlation coefficients, we saw a trend of increased RTOG toxicity in patients with greater variability in their daily treatment times (P=.0575). CSS was significantly improved in patients treated in the AM time period after correction for other pretreatment and treatment variables. While time of day that a patient is treated may be driven by patient specific socio-economic factors not easily captured in the medical record, we cannot rule out a biologic basis for these provocative findings.

Immunotherapy Time of Infusion Impacts Survival in Head and Neck Cancer: A Propensity Score Matched Analysis

Immunotherapy time of infusion impacts survival in head and neck cancer: A propensity score matched analysis

Immune checkpoint inhibitor infusion times and clinical outcomes in patients with melanoma

Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis

Association of circadian timing of initial infusions of immune checkpoint inhibitors with survival in advanced melanoma

Prognostic value of the timing of immune checkpoint inhibitors infusion in patients with advanced hepatocellular carcinoma.

Impact of Timing of Immunotherapy in Survival among Patients with Advanced Lung Adenocarcinoma Treated with First-Line Immunochemotherapy: A Propensity Score Matching.

Prognostic Implications of Timing of Immunotherapy in Stage IV Non-Small Cell Lung Cancer

Effect of time‐of‐day nivolumab and stereotactic body radiotherapy in metastatic head and neck squamous cell carcinoma: A secondary analysis of a prospective randomized trial

Early Morning Immune Checkpoint Blockade and Overall Survival of Patients with Metastatic Cancer: an In-depth Chronotherapeutic Study

Effect of immunochemotherapy infusion timing, sequence, and interval on prognosis of advanced esophageal cancer: A retrospective cohort study

Time of day determines cancer immunotherapy response

Does Time of Daily Treatment Matter in Radiation Therapy for Head and Neck Cancer?

Factors influencing receipt and time to treatment of immunotherapy relative to chemotherapy in stage III and stage IV melanoma

Impact of time-of-day on nivolumab monotherapy infusion in patients with metastatic gastric cancer.

Impact of time-of-day administration of immunotherapy on survival in metastatic renal cell carcinoma: the MOUSEION-09 meta-analysis

Survival Is Worse in Patients Completing Immunotherapy Prior to SBRT/SRS Compared to Those Receiving It Concurrently or After

Impact of the timing of immunotherapy administration on overall survival for resectable non-small cell lung cancer (iACORN study): A Systematic Review and Meta-Analysis of Randomised Trials

Clocking cancer immunotherapy responses

Treatment options for tumor progression after initial immunotherapy in advanced non-small cell lung cancer: A real-world study